

Eugenio Pucci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1247904/publications.pdf>

Version: 2024-02-01

95
papers

4,558
citations

101384

36
h-index

110170

64
g-index

101
all docs

101
docs citations

101
times ranked

4427
citing authors

#	ARTICLE	IF	CITATIONS
1	Advance Care Planning in Neurodegenerative Disorders: A Scoping Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 803.	1.2	12
2	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339.	1.7	3
3	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.	1.4	11
4	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.	1.4	7
5	Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. <i>BMJ Open</i> , 2021, 11, e052012.	0.8	4
6	The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care system's preparedness. <i>Neurological Sciences</i> , 2021, 42, 799-804.	0.9	12
7	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.5	54
8	Construction of a resource for advance care planning in multiple sclerosis (ConCure-SM): Results of cognitive debriefing with users. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118081.	0.3	0
9	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	1.4	52
10	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1765-1774.	1.4	10
11	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	0.9	29
12	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	3.7	32
13	Conflicts of interest and Scientific Societies. <i>Neurological Sciences</i> , 2020, 41, 2095-2102.	0.9	4
14	There is an urgent need for palliative care specialists in MS – Yes. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1710-1711.	1.4	4
15	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.	1.1	21
16	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis. <i>The Cochrane Library</i> , 2019, 5, CD009903.	1.5	7
17	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	0.9	71
18	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	0.9	35

#	ARTICLE	IF	CITATIONS
19	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.	3.8	336
20	Management of psychogenic non-epileptic seizures: a multidisciplinary approach. <i>European Journal of Neurology</i> , 2019, 26, 205.	1.7	64
21	Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.	1.7	12
22	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [<i>Mult. Scler. Relat. Disord.</i> (2017)]. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 166.	0.9	0
23	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	0.9	22
24	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	1.4	37
25	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. <i>Journal of Neurology</i> , 2018, 265, 2851-2860.	1.8	43
26	Silent lesions on MRI imaging " Shifting goal posts for treatment decisions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1569-1577.	1.4	8
27	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.3	22
28	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	4.5	20
29	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	1.4	30
30	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	0.9	49
31	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	4.9	134
32	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	2.8	34
33	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.5	38
34	Data quality evaluation for observational multiple sclerosis registries. <i>Multiple Sclerosis Journal</i> , 2017, 23, 647-655.	1.4	64
35	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	1.4	18
36	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	3.7	94

#	ARTICLE	IF	CITATIONS
37	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	3.7	281
38	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. <i>European Journal of Neurology</i> , 2016, 23, 729-736.	1.7	21
39	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1343-1349.	0.9	63
40	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	0.8	33
41	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1133-1137.	0.9	76
42	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	2.8	158
43	Need for palliative care for neurological diseases. <i>Neurological Sciences</i> , 2016, 37, 1581-1587.	0.9	28
44	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	1.4	34
45	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	2.8	143
46	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989.	1.7	32
47	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 405.	4.5	100
48	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	3.7	162
49	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	1.4	36
50	Natalizumab Treatment in Multiple Sclerosis Patients: A Multicenter Experience in Clinical Practice in Italy. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 147-154.	1.0	23
51	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	1.4	148
52	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency in people with multiple sclerosis: a summary of a Cochrane systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 405-410.	0.9	10
53	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	3.7	140
54	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	1.1	26

#	ARTICLE	IF	CITATIONS
55	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 893.	1.0	28
56	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	1.4	56
57	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	0.9	37
58	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. <i>The Cochrane Library</i> , 2012, 12, CD009903.	1.5	3
59	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.3	35
60	Persistent vegetative state: an ethical reappraisal. <i>Neurological Sciences</i> , 2012, 33, 695-700.	0.9	2
61	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	1.1	35
62	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	1.1	166
63	Natalizumab for relapsing remitting multiple sclerosis. <i>The Cochrane Library</i> , 2011, , CD007621.	1.5	55
64	Ethical issues in end of life treatments for patients with dementia. <i>European Journal of Neurology</i> , 2010, 17, 774-779.	1.7	27
65	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. <i>Multiple Sclerosis Journal</i> , 2010, 16, 100-111.	1.4	50
66	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1393-1405.	1.4	64
67	Understanding information on clinical trials by persons with Alzheimerâ€™s dementia. A pilot study. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 158-166.	1.4	7
68	Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1023-1028.	0.9	42
69	Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsingâ€“remitting multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 266, 44-50.	0.3	11
70	Participation in medical decision-making: Attitudes of Italians with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2008, 275, 86-91.	0.3	63
71	Communicating the diagnosis of multiple sclerosis - a qualitative study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 763-769.	1.4	77
72	Amantadine for fatigue in multiple sclerosis. <i>The Cochrane Library</i> , 2007, , CD002818.	1.5	99

#	ARTICLE	IF	CITATIONS
73	Ethical questions in the treatment of subjects with dementia. Part I. Respecting autonomy: awareness, competence and behavioural disorders. <i>Neurological Sciences</i> , 2007, 28, 216-231.	0.9	26
74	Message for caregivers of dementia with Lewy bodies patients: hallucinations can be pleasurable for your patient. Cope with your embarrassment and empathize. <i>European Journal of Neurology</i> , 2006, 13, 666-666.	1.7	3
75	What do Italians at high risk of stroke know about ischaemic stroke? A survey among a group of subjects undergoing neuro-sonographic examination. <i>Neurological Sciences</i> , 2006, 27, 7-13.	0.9	15
76	Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb. <i>Multiple Sclerosis Journal</i> , 2006, 12, 72-76.	1.4	42
77	Development of an ELISA Test for Determination of the Urinary Trypsin Inhibitor: Analytical Performance and Applications. <i>Journal of Immunoassay and Immunochemistry</i> , 2005, 26, 43-56.	0.5	2
78	Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis. <i>Neurological Sciences</i> , 2004, 24, 375-383.	0.9	37
79	General practitioners facing dementia: are they fully prepared?. <i>Neurological Sciences</i> , 2004, 24, 384-389.	0.9	37
80	Why physicians need to look more closely at the use of complementary and alternative medicine by multiple sclerosis patients. <i>European Journal of Neurology</i> , 2004, 11, 263-267.	1.7	41
81	Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. <i>Journal of the Neurological Sciences</i> , 2004, 222, 99-104.	0.3	122
82	Corrigendum to "Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial" [J. Neurol. Sci. 222 (2004) 99-104]. <i>Journal of the Neurological Sciences</i> , 2004, 224, 113.	0.3	1
83	Is the internet transforming the physician-consumer relationship? Preliminary data in a neurological setting. <i>European Journal of Neurology</i> , 2003, 10, 192-192.	1.7	15
84	Relatives' attitudes towards informing patients about the diagnosis of Alzheimer's disease. <i>Journal of Medical Ethics</i> , 2003, 29, 51-54.	1.0	43
85	Aminopyridines for symptomatic treatment in multiple sclerosis. <i>The Cochrane Library</i> , 2002, , .	1.5	37
86	Information and Competency for Consent to Pharmacologic Clinical Trials in Alzheimer Disease: An Empirical Analysis in Patients and Family Caregivers. <i>Alzheimer Disease and Associated Disorders</i> , 2001, 15, 146-154.	0.6	35
87	Cytochemistry of Intraplatelet Ca ⁺⁺ Spots as a Peripheral Marker of Age-related Brain Impairment. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 164-166.	1.8	3
88	Topographical Disorientation Consequent to Amnesia of Spatial Location in A Patient with Right Parahippocampal Damage. <i>Cortex</i> , 2000, 36, 427-434.	1.1	37
89	Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2000, 101, 224-228.	1.0	46
90	EEG power spectrum differences in early and late onset forms of Alzheimer's disease. <i>Clinical Neurophysiology</i> , 1999, 110, 621-631.	0.7	63

#	ARTICLE	IF	CITATIONS
91	EEG spectral analysis in Alzheimer's disease and different degenerative dementias. Archives of Gerontology and Geriatrics, 1998, 26, 283-297.	1.4	31
92	Hippocampus and Parahippocampal Gyrus Linear Measurements Based on Magnetic Resonance in Alzheimer's Disease. European Neurology, 1998, 39, 16-25.	0.6	28
93	EEG power spectrum typical of vascular dementia in a subgroup of Alzheimer patients. Archives of Gerontology and Geriatrics, 1996, 23, 139-151.	1.4	18
94	An EEG power index (eyes open vs. eyes closed) to differentiate Alzheimer's from vascular dementia and healthy ageing. Archives of Gerontology and Geriatrics, 1996, 22, 245-260.	1.4	12
95	EEG spectral analysis in vascular and Alzheimer dementia. Electroencephalography and Clinical Neurophysiology, 1995, 94, 313-325.	0.3	93